Methods for the ex vivo modification of the surfaces of viable tissue result in tissue modifications that are stable and/or result in the controlled release of active compounds, and are expected to provide effective protection for transplanted tissue subsequent to transplant.

The present invention relates to a use of CD133 involved in resistance to an EGFR-targeting agent in colon cancer. The CD133 protein may be used as a novel target protein for diagnosing and treating resistant cancer as well as general cancer.

A population of cells possesses enhanced selectin binding based upon a fucosylated selectin ligand present on a surface thereof. Methods of producing the population of cells, along with therapeutic methods of using the cells, are also disclosed.

The present invention provides, in certain aspects, a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15), and methods for producing such cells. The invention further provides methods of using a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15) to treat cancer in a subject or to enhance expansion and/or survival of NK cells.

Methods of treatment are provided herein, including administration of a population cells modified to enforce expression of an E-selectin and/or an L-selectin ligand, the modified cell population having a cell viability of at least 70% after a treatment to enforce such expression.

A device is directed to simulating a function of a tissue, and includes a first structure defining a first chamber, a second structure defining a second chamber, and a porous membrane located at an interface region between the first chamber and the second chamber. The membrane has a first side facing toward the first chamber and a second side facing toward the second chamber, the membrane separating the first chamber from the second chamber. The first side includes a fluid-permeable, stimulus-responsive polymer gel thereon, the second side including at least one layer of cells adhered thereon.

Methods of using magnetic display cells to replace secondary antibodies and magnetic beads in any cell manipulation methods. Cells displaying ligands for target cells are magnetized, and then used to bind the target cells. The complex can then be collected in a magnetic field, and thereby manipulated according to the application needs.

Compositions are provided including NK cells that express chimeric antigen receptors (CARs) specific to CD19 and Her2 and a plurality of cell surface-bound multilamellar liposomal vesicles loaded with one or more anti-cancer therapeutics at an effective amount for inhibiting or killing tumor cells without causing toxicity to the NK cells. Methods of using these compositions to treat a subject with tumor are also provided, including administering an effective amount of the CAR-engineered NK cells, where an effective amount of anti-tumor therapeutics are delivered in particles (e.g., crosslinked multilamellar liposomal vesicles) that are bound to the surface of these CAR-engineered NK cells, without causing toxicity to the carrier NK cells.

A pair of pyrrole-imidazole polyamides conjugated with nucleic acid-based cooperation system is provided.

A method for the optoinjection of exogenous material in a recipient biological cell is disclosed and comprises: placing a biological cell on a planar surface of a substrate, transmitting a sub-ns pulsed laser beam through a variable convergence/divergence collimator; focusing the laser beam in a focal spot positioned along an axial direction substantially perpendicular to the substrate; moving the focal spot towards the cell along the axial direction by continuously varying the electric control signal from a first amplitude value a second amplitude value the second amplitude value of the control signal is selected such that the second axial position is positioned inside the cell.